adalimumab + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

Apr 16, 2013 → Apr 14, 2017

NCT ID

NCT01808118

About adalimumab + Placebo

adalimumab + Placebo is a phase 3 stage product being developed by AbbVie for Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01808118. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

6 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (6) Terminated (1) Active (14)

✅AdalimumabAbbVieApproved

✅Secukinumab 150 milligram [Cosentyx]NovartisApproved

✅Secukinumab + Placebo + SecukinumabNovartisApproved

✅etanercept + etanercept + placeboPfizerApproved

✅Tofacitinib 5 MGPfizerApproved

✅Certolizumab PegolUCBApproved

🔄Brodalumab + PlaceboKyowa KirinPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02065557	Phase 3	Completed	Oct 13, 2014	Feb 7, 2020	Ulcerative Colitis
NCT02065570	Phase 3	Completed	May 1, 2014	Jan 30, 2020	Crohn's Disease
NCT01893996	Approved	Completed	Jul 1, 2013	Jul 1, 2017	Rheumatoid Arthritis
NCT01808118	Phase 3	Completed	Apr 16, 2013	Apr 14, 2017	Axial Spondyloarthritis
NCT01670240	Phase 3	Completed	Aug 1, 2012	Jan 1, 2016	Ulcerative Colitis
NCT01646073	Phase 3	Completed	Aug 1, 2012	Dec 1, 2013	Plaque Psoriasis
NCT01468207	Phase 3	Completed	Nov 1, 2011	Jan 1, 2014	Hidradenitis Suppurativa (HS)
NCT01468233	Phase 3	Completed	Nov 1, 2011	Apr 1, 2014	Hidradenitis Suppurativa (HS)
NCT01064856	Phase 3	Completed	Feb 1, 2010	May 1, 2014	Peripheral Spondyloarthritis

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
Brodalumab + Placebo	Kyowa Kirin	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	29
Upadacitinib	AbbVie	Pre-clinical	33
Adalimumab	AbbVie	Approved	35
Adalimumab + Placebo + Open-label Adalimumab	AbbVie	Phase 3	40
Treatment	Merck	Pre-clinical	66
Golimumab	Merck	Phase 3	40
Tulisokibart + Placebo	Merck	Phase 2	42
Secukinumab 150 milligram [Cosentyx]	Novartis	Approved	39
secukinumab	Novartis	Pre-clinical	26
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47
Secukinumab + Secukinumab and Placebo	Novartis	Phase 3	40
Secukinumab/Adalimumab-Biosimilar	Novartis	Phase 3	40
Brodalumab 210 mg + Placebo	Amgen	Phase 2	27
Etanercept 25mg + Sulfasalazine	Pfizer	Phase 2	31